IRADIMED CORP (IRMD) Stock Fundamental Analysis
NASDAQ:IRMD - Nasdaq - US46266A1097 - Common Stock - Currency: USD
Taking everything into account, IRMD scores 7 out of 10 in our fundamental rating. IRMD was compared to 187 industry peers in the Health Care Equipment & Supplies industry. IRMD gets an excellent profitability rating and is at the same time showing great financial health properties. IRMD has a correct valuation and a medium growth rate. These ratings would make IRMD suitable for quality investing!
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
In the past year IRMD had a positive cash flow from operations.
In the past 5 years IRMD has always been profitable.
Each year in the past 5 years IRMD had a positive operating cash flow.
1.2 Ratios
IRMD has a Return On Assets of 19.45%. This is amongst the best in the industry. IRMD outperforms 97.86% of its industry peers.
Looking at the Return On Equity, with a value of 21.97%, IRMD belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
IRMD has a Return On Invested Capital of 19.22%. This is amongst the best in the industry. IRMD outperforms 97.86% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 7.89%.
The last Return On Invested Capital (19.22%) for IRMD is above the 3 year average (18.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.45% | ||
| ROE | 21.97% | ||
| ROIC | 19.22% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
IRMD has a better Profit Margin (26.33%) than 96.26% of its industry peers.
In the last couple of years the Profit Margin of IRMD has remained more or less at the same level.
IRMD's Operating Margin of 30.14% is amongst the best of the industry. IRMD outperforms 98.93% of its industry peers.
In the last couple of years the Operating Margin of IRMD has grown nicely.
With an excellent Gross Margin value of 76.91%, IRMD belongs to the best of the industry, outperforming 89.84% of the companies in the same industry.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.14% | ||
| PM (TTM) | 26.33% | ||
| GM | 76.91% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
IRMD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IRMD has more shares outstanding
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 41.15 indicates that IRMD is not in any danger for bankruptcy at the moment.
IRMD has a Altman-Z score of 41.15. This is amongst the best in the industry. IRMD outperforms 99.47% of its industry peers.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 41.15 |
ROIC/WACC2.13
WACC9.02%
2.3 Liquidity
A Current Ratio of 8.87 indicates that IRMD has no problem at all paying its short term obligations.
The Current ratio of IRMD (8.87) is better than 90.37% of its industry peers.
A Quick Ratio of 7.62 indicates that IRMD has no problem at all paying its short term obligations.
The Quick ratio of IRMD (7.62) is better than 90.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.87 | ||
| Quick Ratio | 7.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.04% over the past year.
IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
The Revenue has grown by 11.04% in the past year. This is quite good.
Measured over the past years, IRMD shows a quite strong growth in Revenue. The Revenue has been growing by 13.71% on average per year.
EPS 1Y (TTM)11.04%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
Revenue 1Y (TTM)11.04%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%10.87%
3.2 Future
The Earnings Per Share is expected to grow by 10.91% on average over the next years. This is quite good.
IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.23% yearly.
EPS Next Y7.25%
EPS Next 2Y10.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.78%
Revenue Next 2Y9.23%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 34.06 indicates a quite expensive valuation of IRMD.
Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than the industry average as 71.12% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.35, IRMD is valued a bit more expensive.
Based on the Price/Forward Earnings ratio of 28.69, the valuation of IRMD can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 71.12% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.19. IRMD is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.06 | ||
| Fwd PE | 28.69 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than the industry average as 70.59% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 73.80% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.77 | ||
| EV/EBITDA | 29.47 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.69
PEG (5Y)2.45
EPS Next 2Y10.91%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.16%, IRMD has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 1.85, IRMD pays a better dividend. On top of this IRMD pays more dividend than 95.19% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.42, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
5.2 History
IRMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
39.74% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.74%
EPS Next 2Y10.91%
EPS Next 3YN/A
58.24
-0.21 (-0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners58.77%
Inst Owner Change0.62%
Ins Owners36.8%
Ins Owner Change0%
Market Cap740.81M
Analysts82.5
Price Target72.42 (24.35%)
Short Float %2.85%
Short Ratio6.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.74%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.96%
Max EPS beat(2)0.43%
EPS beat(4)3
Avg EPS beat(4)5.2%
Min EPS beat(4)-1.96%
Max EPS beat(4)12.81%
EPS beat(8)6
Avg EPS beat(8)6.55%
EPS beat(12)10
Avg EPS beat(12)7.11%
EPS beat(16)14
Avg EPS beat(16)13.86%
Revenue beat(2)0
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)-0.71%
Revenue beat(4)0
Avg Revenue beat(4)-0.72%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)4
Avg Revenue beat(12)-0.25%
Revenue beat(16)7
Avg Revenue beat(16)0.78%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.06 | ||
| Fwd PE | 28.69 | ||
| P/S | 9.86 | ||
| P/FCF | 53.77 | ||
| P/OCF | 28.46 | ||
| P/B | 8.23 | ||
| P/tB | 8.54 | ||
| EV/EBITDA | 29.47 |
EPS(TTM)1.71
EY2.94%
EPS(NY)2.03
Fwd EY3.49%
FCF(TTM)1.08
FCFY1.86%
OCF(TTM)2.05
OCFY3.51%
SpS5.91
BVpS7.08
TBVpS6.82
PEG (NY)4.69
PEG (5Y)2.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.45% | ||
| ROE | 21.97% | ||
| ROCE | 24.29% | ||
| ROIC | 19.22% | ||
| ROICexc | 41.77% | ||
| ROICexgc | 45.2% | ||
| OM | 30.14% | ||
| PM (TTM) | 26.33% | ||
| GM | 76.91% | ||
| FCFM | 18.33% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexcg growth 3Y-6.9%
ROICexcg growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1559.79% | ||
| Cap/Sales | 16.31% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 111.09% | ||
| Profit Quality | 69.64% | ||
| Current Ratio | 8.87 | ||
| Quick Ratio | 7.62 | ||
| Altman-Z | 41.15 |
F-Score5
WACC9.02%
ROIC/WACC2.13
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)11.04%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
EPS Next Y7.25%
EPS Next 2Y10.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.04%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%10.87%
Revenue Next Year8.78%
Revenue Next 2Y9.23%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.94%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y96.33%
OCF growth 3Y31.53%
OCF growth 5Y20.16%